): This Surgical Oncology Training program is designed to attract and train physicians with a clinical background in surgery in a two- year fellowship of basic oncological research. The major emphasis of this program will be on the development of research skills which have a translational applicability to clinical surgical oncology. This will be accomplished through an intense, personal involvement of the trainee with an established cancer research investigator at the UNC Lineberger Comprehensive Cancer Center who has experience in the training of physician scientists. Each trainee has a clinical mentor in surgical oncology to help to coordinate the trainee's translational research focus. The first year of the program emphasizes research methodology, coursework, and basic science techniques to ensure that the fellows receive the knowledge and methodology in various fields of cancer research. Formal coursework will be completed by the trainee in individualized programs in areas such as biostatistics, immunology, molecular biology, signal transduction, or epidemiology. As the individual's own research project matures, they will present their work to a basic science review committee to ensure they are able to defend their interpretation of their experiments. Selection of the trainees will be competitive and preference will be for fellows who have completed their clinical training and whose identification of problem areas in oncology has been enhanced by the clinical experience. Candidates will be considered who have completed two to three years of residency if they demonstrate exceptional promise as academic surgeons. A total of two trainees will participate in the program, one fellow being selected annually for a two year period.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Institutional National Research Service Award (T32)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Eckstein, David J
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of North Carolina Chapel Hill
Internal Medicine/Medicine
Schools of Medicine
Chapel Hill
United States
Zip Code
Tignanelli, Christopher J; Herrera Loeza, Silvia G; Yeh, Jen Jen (2014) KRAS and PIK3CA mutation frequencies in patient-derived xenograft models of pancreatic and colorectal cancer are reflective of patient tumors and stable across passages. Am Surg 80:873-7
Damrauer, Jeffrey S; Hoadley, Katherine A; Chism, David D et al. (2014) Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci U S A 111:3110-5
Chism, David D; De Silva, Dinuka; Whang, Young E (2014) Mechanisms of acquired resistance to androgen receptor targeting drugs in castration-resistant prostate cancer. Expert Rev Anticancer Ther 14:1369-78
Kasamon, Yvette L; Brodsky, Robert A; Borowitz, Michael J et al. (2013) Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemia. Leuk Lymphoma 54:483-90
Kasamon, Yvette L; Jacene, Heather A; Gocke, Christopher D et al. (2012) Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma. Blood 119:4129-32
Kasamon, Yvette L; Jones, Richard J; Gocke, Christopher D et al. (2011) Extended follow-up of autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide (4-HC) purging for indolent or transformed non-Hodgkin lymphomas. Biol Blood Marrow Transplant 17:365-73
Goicoechea, Silvia M; Bednarski, Brian; Stack, Christianna et al. (2010) Isoform-specific upregulation of palladin in human and murine pancreas tumors. PLoS One 5:e10347
Kimple, Randall J; Vaseva, Angelina V; Cox, Adrienne D et al. (2010) Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status. Clin Cancer Res 16:912-23
Kasamon, Y L; Jones, R J; Brodsky, R A et al. (2010) Immunologic recovery following autologous stem-cell transplantation with pre- and posttransplantation rituximab for low-grade or mantle cell lymphoma. Ann Oncol 21:1203-10
Goicoechea, S M; Bednarski, B; GarcĂ­a-Mata, R et al. (2009) Palladin contributes to invasive motility in human breast cancer cells. Oncogene 28:587-98

Showing the most recent 10 out of 22 publications